Orchid Pharma Limited
All news and filings related to Orchid Pharma Limited.
View all news & filings- Low impact
Orchid Pharma holds 33rd AGM on Sep 29, 2026; discusses financial statements
Orchid Pharma Limited conducted its 33rd AGM on September 29, 2026. Key agenda items included adopting FY26 financial statements, reappointment of Mr. Mridul Dhanuka, approving material related party transactions, and appointing Mr. Arjun Dhanuka as Whole-time Director. E-voting results are expected within two working days.
Read the summary - Low impact
Orchid Pharma: Trading Window Closed for Q2 FY27 Financial Results
Orchid Pharma Limited will close its trading window from October 1, 2026, for Q2 FY27 financial results. The closure will last until 48 hours after the announcement of the unaudited results. Designated persons are restricted from trading during this period.
Read the summary - Low impact
Orchid Pharma Equity Shares Listed on NSE & BSE Effective Sept 23, 2026
Orchid Pharma Limited announced that 4,45,86,052 equity shares, allotted under a Scheme of Amalgamation, are listed and admitted to dealings on NSE and BSE. The listing is effective September 23, 2026. This follows a previous intimation on August 01, 2026.
Read the summary - Low impact
Orchid Pharma Buys Land in Tamil Nadu, Concluding DBS Bank Lease Arrangement
Orchid Pharma Limited has purchased land in Kancheepuram District, Tamil Nadu, concluding its lease arrangement with DBS Bank India Limited for the property. This acquisition provides clarity on the company's ownership.
Read the summary - Low impact
Orchid Pharma to Participate in Investor Roadshow in Mumbai from Sep 28-30
Orchid Pharma Limited will participate in an Investor Roadshow in Mumbai from September 28-30, 2026. Whole Time Director Mr. Mridul Dhanuka will attend. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
Orchid Pharma Files BRSR Report for FY25-26
Orchid Pharma Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report is part of the Annual Report and is available on the company's website.
Read the summary - Medium impact
Orchid Pharma Announces 33rd AGM on Sep 29, 2026, to Discuss FY26 Results & Director Appointments
Orchid Pharma Limited will hold its 33rd AGM on September 29, 2026, via VC/OAVM. The meeting will consider FY26 financial statements, reappoint Mr. Mridul Dhanuka, and appoint Mr. Arjun Dhanuka as Whole-time Director. Approval for related party transactions up to ₹400 crore with Otsuka Chemicals and ratification of Cost Auditor's remuneration are also on the agenda.
Read the summary - Medium impact
Orchid Pharma Appoints Arjun Dhanuka as Whole-Time Director, Schedules 33rd AGM
Orchid Pharma's Board appointed Arjun Dhanuka as Whole-Time Director until September 2031. The company will hold its 33rd AGM on September 29, 2026. The cut-off for AGM notice and e-voting is September 4, 2026. Cost auditors for FY27 were also appointed.
Read the summary - Medium impact
Orchid Pharma Appoints Arjun Dhanuka as Whole-Time Director, Schedules 33rd AGM
Orchid Pharma's Board meeting on Sept 3, 2026, approved appointing M/s. J Karthikeyan & Associates as Cost Auditors for FY27. Mr. Arjun Dhanuka was appointed Whole-Time Director for five years. The 33rd AGM is scheduled for Sept 29, 2026, with cut-off dates for notice and e-voting set.
Read the summary - Medium impact
Orchid Pharma Releases Q1 FY27 Earnings Call Transcript
Orchid Pharma's Q1 FY27 earnings call transcript reveals a 15% revenue growth to ₹304 crore. The company is focused on integrating Dhanuka Laboratories and reviving its cephalosporin business. Key projects like Exblifep, Cefiderocol, and 7-ACA are progressing, with the latter two targeting commissioning in late 2026 and early 2027, respectively.
Read the summary - Low impact
Orchid Pharma Releases Audio Recording of Q1 FY27 Earnings Call
Orchid Pharma has uploaded the audio recording of its Q1 FY27 earnings call held on August 21, 2026. The call discussed unaudited financial results for the quarter ended June 30, 2026. No video recording is available.
Read the summary - Low impact
Orchid Pharma Releases Q1 FY27 Investor Presentation for Period Ended June 30, 2026
Orchid Pharma Limited released its investor presentation for Q1 FY27 ended June 30, 2026. This follows an earlier intimation about the Analysts/Investors Earning Call scheduled for August 21, 2026. The presentation details the company's financial performance for the quarter and is available on their website.
Read the summary - Low impact
Orchid Pharma Schedules Q1FY27 Earnings Call for August 21, 2026
Orchid Pharma Limited will host an Investors Earning Call on August 21, 2026, at 3:00 PM IST to discuss financial results for the quarter ended June 30, 2026. Management representatives including the Managing Director, Whole Time Director, and CFO will participate.
Read the summary - Low impact
Orchid Pharma: Monitoring Agency Report for Q1 FY27 on QIP Proceeds Utilization
Orchid Pharma's Q1 FY27 Monitoring Agency Report confirms no deviation in QIP fund utilization. ₹400 crore QIP proceeds allocation was revised with shareholder approval on September 20, 2025. ₹357.16 crore utilized, ₹37.38 crore unutilized. Jammu facility operations delayed to February 2027.
Read the summary - Medium impact
Orchid Pharma Approves Revised FY26 Financials Post-Amalgamation
Orchid Pharma's Board approved revised FY26 standalone and consolidated financial results post-amalgamation with Dhanuka Laboratories, effective July 10, 2026. Standalone and consolidated net sales for FY26 were ₹1,23,277.84 lakhs. The company also completed the acquisition of Allecra Therapeutics assets, gaining full global ownership of Enmetazobactam.
Read the summary - Medium impact
Orchid Pharma Q1 FY27 Results: Profit Before Tax at ₹1,193.72 Lakhs
Orchid Pharma reported Q1 FY27 unaudited results. Standalone Profit Before Tax was ₹1,193.72 lakhs. Consolidated Profit Before Tax was ₹264.95 lakhs. Total income from operations was ₹30,417.13 lakhs on both standalone and consolidated bases. The company also provided an update on QIP fund utilization.
Read the summary - Medium impact
Orchid Pharma Allots 4.45 Cr Equity Shares Pursuant to Amalgamation Scheme
Orchid Pharma Limited has approved the allotment of 4,45,86,052 equity shares of Rs. 10 each to Dhanuka Laboratories Limited shareholders as part of the amalgamation scheme. The new shares will be listed on NSE and BSE. Post-allotment, the company's paid-up capital is Rs. 59.88 crore.
Read the summary - Medium impact
Orchid Pharma Allots 4.45 Cr Shares Post Amalgamation with Dhanuka Labs
Orchid Pharma will issue 4,45,86,052 equity shares to Dhanuka Laboratories shareholders as part of an amalgamation scheme. The shares will be listed on NSE and BSE. Post-allotment, Orchid Pharma's paid-up capital increases to ₹59.89 crore.
Read the summary - Low impact
Orchid Pharma's Whole Time Director to Participate in Investor Roadshow in Singapore
Mr. Mridul Dhanuka, Whole Time Director of Orchid Pharma Limited, will attend an investor roadshow in Singapore from July 29-31, 2026. The event will involve physical group meetings. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
Orchid Pharma Files SEBI Compliance Certificate for Q1 FY27
Orchid Pharma Limited submitted a confirmation certificate for Q1 FY27 ended June 30, 2026. The certificate, issued by M/s. Abhipra Capital Limited, confirms compliance with SEBI (Depositories and Participants) Regulations, 2018.
Read the summary - Medium impact
Orchid Pharma Sets July 23, 2026, as Record Date for Share Exchange Post-Amalgamation
Orchid Pharma's Board approved the amalgamation with Dhanuka Laboratories, effective July 10, 2026. The record date for share issuance is July 23, 2026. The share exchange ratio is 161:5. Authorized capital increased to ₹164.51 crore.
Read the summary - High impact
Orchid Pharma Completes Amalgamation with Dhanuka Labs; Sets Record Date July 23
Orchid Pharma's Board approved the amalgamation with Dhanuka Laboratories, effective July 10, 2026. The authorized capital increased to ₹164.51 crore. July 23, 2026, is the record date for share allotment. The exchange ratio is 161 OPL shares for every 5 DLL shares.
Read the summary - Medium impact
Orchid Pharma Amalgamation with Dhanuka Labs Effective July 10, 2026
Orchid Pharma Limited's amalgamation with Dhanuka Laboratories Limited is now effective as of July 10, 2026. The scheme became effective upon filing the NCLT order with the Registrar of Companies. Dhanuka Laboratories is dissolved without winding up. The appointed date for the scheme is April 01, 2024.
Read the summary - High impact
Orchid Pharma's Amalgamation with Dhanuka Laboratories Approved
Orchid Pharma Limited's amalgamation with Dhanuka Laboratories Limited has been approved by the NCLT, Chennai. The Appointed Date is April 01, 2024. The merger aims to create a larger entity with potential sales turnover of ₹1400-1500 crore. Orchid Pharma will issue 161 shares for every 5 shares of Dhanuka Laboratories.
Read the summary - Low impact
Orchid Pharma Receives GST Order for ₹1.67 Cr Refund Recovery; Plans Appeal
Orchid Pharma received an order from GST authorities for recovery of ₹1.67 Cr refund plus interest. The company plans to appeal, believing the demand is unjustified. Management expects no material financial impact due to prior acquisition under a resolution plan.
Read the summary - Medium impact
Orchid Pharma Releases Q4 FY26 Earnings Call Transcript
Orchid Pharma's Q4 FY26 standalone revenue was INR 238 crore, with EBITDA at INR 42.3 crore. Full-year FY26 revenue was INR 811 crore and EBITDA INR 101 crore. The company sees stabilization in the Cephalosporin industry and is building an anti-infectives platform. Merger with Dhanuka Labs is pending. 7ACA project commissioning by Q1 2027.
Read the summary - Low impact
Orchid Pharma: Audio Recording of Analysts/Investors Earnings Call Available
Orchid Pharma Limited released the audio recording of its Analysts/Investors Earnings Call held on May 26, 2026. The recording is available via a provided link. The company confirmed the call was audio-only.
Read the summary - Medium impact
Orchid Pharma Investor Presentation: Q4 & FY26 Results, Strategic Growth Initiatives
Orchid Pharma's FY26 standalone revenue was ₹811 crore, down 12% YoY, with PAT at ₹45 crore. Q4 FY26 revenue was ₹238 crore, and PAT was ₹30 crore. The company is building an integrated anti-infectives platform, investing ₹750 crore in 7-ACA integration and ₹200 crore in the Cefiderocol project. Plans include launching 5-6 sterile products in the US by 2030.
Read the summary - Medium impact
Orchid Pharma Q4 FY26 Results: Standalone Profit ₹3060 Cr, Consolidated Profit ₹2378 Cr
Orchid Pharma reported Q4 FY26 standalone profit of ₹3060.37 lakh and consolidated profit of ₹2378.51 lakh. For FY26, standalone profit was ₹4520.79 lakh and consolidated profit was ₹2120.83 lakh. The company appointed an internal auditor for FY27 and completed acquisitions in Germany. Amalgamation with Dhanuka Laboratories is pending NCLT order.
Read the summary - Medium impact
Orchid Pharma Board Approves Q4 FY26 Financials, Appoints Internal Auditor
Orchid Pharma reported audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Standalone net sales for the year were ₹81,132.73 lakhs. The company appointed an Internal Auditor for FY27. Key developments include the completion of Allecra Therapeutics acquisition and an update on the Dhanuka Laboratories amalgamation.
Read the summary - Medium impact
Orchid Pharma Q4 FY26 Results: Net Profit ₹3060 Crore, Approves Internal Auditor Appointment
Orchid Pharma reported Q4 FY26 standalone net profit of ₹3,060.37 lakhs and consolidated net profit of ₹2,378.02 lakhs. The company's Board approved the FY26 audited financial results and appointed the Internal Auditor for FY27. Acquisitions of Allecra Therapeutics assets were completed, and an amalgamation scheme with Dhanuka Laboratories is pending NCLT approval.
Read the summary - Low impact
Orchid Pharma Announces Analyst/Investor Call on 26 May 2026 for FY26 Results
Orchid Pharma will hold an analyst/investor call on May 26, 2026, at 4:30 PM (IST) to discuss Q4FY26 and full-year results. The call is hosted by Systematix Institutional Equities. Key management representatives include Manish Dhanuka, Mridul Dhanuka, and Sunil Kumar Gupta.
Read the summary - Medium impact
Orchid Pharma: Monitoring Agency Report for Q4FY26 Shows No Deviation in Fund Utilization
Orchid Pharma's Q4FY26 Monitoring Agency Report confirms no deviation in the utilization of ₹400 crore QIP proceeds. Shareholder approval in September 2025 allowed for revised fund allocation. The Jammu manufacturing facility faces delays, with operations now expected by February 2027. ₹3.77 crores spent on technical know-how.
Read the summary - Low impact
Orchid Pharma: NCLT Dismisses DBS Bank's Lease Rent Claim
NCLT Chennai dismissed DBS Bank's application for lease rent during CIRP. The order, pronounced on April 02, 2026, and made available on April 10, 2026, has no quantifiable financial impact on Orchid Pharma.
Read the summary - Low impact
Orchid Pharma Files SEBI Compliance Certificate for Q4 FY26
Orchid Pharma Limited submitted a SEBI compliance certificate for Q4 FY26, ending March 31, 2026. The certificate from Abhipra Capital Limited confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Read the summary - Low impact
Orchid Pharma to Participate in Investor Roadshow on April 10, 2026
Orchid Pharma Limited director Mr. Mridul Dhanuka will attend an investor roadshow on April 10, 2026. The event will be a physical group meeting in Gurugram. No price-sensitive information will be disclosed.
Read the summary - Medium impact
Orchid Pharma's Credit Rating Downgraded by CARE Ratings
CARE Ratings downgraded Orchid Pharma's long-term bank facilities (₹207.50 crore) from CARE A- to CARE BBB+ (Stable). Long-term/short-term facilities (₹75.00 crore) also saw a downgrade to CARE BBB+ (Stable) / CARE A2. Short-term facilities (₹84.00 crore) were reaffirmed at CARE A2.
Read the summary - Low impact
Orchid Pharma: Trading Window Closed from April 1, 2026 for FY26 Results
Orchid Pharma Limited will close its trading window from April 1, 2026, for the Q4 and FY26 audited financial results. Trading will be prohibited until 48 hours post-results declaration. The board meeting date for approving results will be announced later.
Read the summary - Medium impact
Orchid Pharma awaits NCLT order on Dhanuka Labs amalgamation scheme
Orchid Pharma Limited is awaiting a formal pronouncement from the NCLT regarding the amalgamation scheme with Dhanuka Laboratories Limited. The order was reserved for pronouncement on March 18, 2026. Further updates will be provided upon receipt of the NCLT order.
Read the summary - Medium impact
Orchid Pharma Q3 FY26 Earnings Call Transcript Released
Orchid Pharma reported Q3 FY26 sales of ₹207 crore (down 5% YoY) and EBITDA of 6% (vs 17% YoY) due to global antibiotic market stress. The company is focusing on cost control and R&D, with differentiated products like Exblifep showing progress. Mechanical completion for the 7ACA project is targeted by September, and Cefiderocol production is slated for December 2026.
Read the summary - Low impact
Orchid Pharma Releases Audio Recording of Q3 FY26 Earnings Call
Orchid Pharma released the audio recording of its Q3 FY26 earnings call held on February 12, 2026. The call discussed financial performance for the quarter ended December 31, 2025. The audio recording is available on the company's website.
Read the summary - Low impact
Orchid Pharma: Monitoring Agency Report for Q3 FY26 on QIP Proceeds Utilization
Orchid Pharma's QIP proceeds utilization report for Q3 FY26 shows full utilization of ₹36 lakhs for API facility capex by June 2025. Land acquisition for Jammu facility is progressing, with remaining land registration expected by March 2026. No deviation from QIP objects noted.
Read the summary - Medium impact
Orchid Pharma Q3 FY26 Results: Sales ₹207 Cr, EBITDA ₹13 Cr, PBT -₹6 Cr
Orchid Pharma reported Q3 FY26 standalone results with sales at ₹207 crore, down 5% YoY. EBITDA declined 65% to ₹13 crore, and PBT was -₹6 crore. For 9M FY26, sales were ₹574 crore, down 16% YoY, with EBITDA at ₹58 crore and PBT at ₹15 crore. An investor presentation was shared on February 11, 2026.
Read the summary - Medium impact
Orchid Pharma Board Approves Q3 FY26 Results; Amalgamation Scheme Progresses
Orchid Pharma reported unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025. Standalone net sales were ₹20,726.70 lakhs for the quarter and ₹57,372.00 lakhs for nine months. Consolidated net sales were ₹20,726.70 lakhs and ₹57,372.00 lakhs respectively. The Board approved the results and noted progress on the amalgamation scheme with Dhanuka Laboratories Limited, with the next NCLT hearing on March 02, 2026.
Read the summary - Medium impact
Orchid Pharma Board Approves Q3 FY26 Unaudited Financial Results
Orchid Pharma reported Q3 FY26 unaudited results with standalone and consolidated net sales of ₹20,726.70 lakhs. The company recognized ₹711.27 lakhs in exceptional items due to new labor codes. QIP proceeds of ₹39,180 lakhs are being utilized, with ₹6,198 lakhs remaining. Amalgamation with Dhanuka Laboratories is progressing, with the next NCLT hearing on March 2, 2026.
Read the summary - Low impact
Orchid Pharma Schedules Q3FY26 Earnings Call for Feb 12
Orchid Pharma Limited will host an Analysts/Investors Earnings Call on February 12, 2026, at 4:30 PM IST to discuss Q3FY26 results ended December 31, 2025. Management including MD Manish Dhanuka will attend.
Read the summary - Low impact
Orchid Pharma Files Compliance Certificate for Q3 FY26 under SEBI Regulations
Orchid Pharma Limited submitted a compliance certificate for Q3 FY26, ending December 31, 2025. The certificate, issued by Registrar Abhipra Capital Limited, confirms compliance with SEBI (Depositories and Participants) Regulations, 2018. The company has requested the stock exchanges to take this on record.
Read the summary - Low impact
Orchid Pharma: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results
Orchid Pharma Limited will close its trading window from January 1, 2026. This closure is in anticipation of the Q3 FY26 financial results, which will be announced after a board meeting. The window will reopen 48 hours post-announcement.
Read the summary - Medium impact
Orchid Pharma Q2 FY26 Earnings Call Transcript
Orchid Pharma's Q2 FY26 sales declined 13% YoY, but improved sequentially. Gross margins were impacted. The company completed the acquisition of Enmetazobactam global rights and expects licensing deals. Cefiderocol project is on track.
Read the summary - Low impact
Monitoring Agency Report for Quarter II Ended September 30, 2025
Orchid Pharma submits Monitoring Agency Report for Q2 ended Sept 30, 2025, detailing utilization of QIP proceeds and revisions approved in AGM held on September 20, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio